secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0000950170-25-095334
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Ultragenyx UX111 BLA; resubmission planned with 6-month review
--------------------------------------------------------------------------------

- FDA CRL received July 11, 2025, for UX111 (ABO-102) AAV gene therapy for Sanfilippo syndrome type A.
- CRL requests additional CMC documentation and addresses observations from manufacturing facility inspections.
- Company states observations are readily addressable and unrelated to product quality; clinical data package not cited.
- FDA acknowledged robust neurodevelopmental outcome data and supportive biomarker evidence; updated clinical data requested.
- Ultragenyx plans to resubmit BLA within months, expecting up to 6-month FDA review period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025095334/0000950170-25-095334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025095334/rare-20250711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-095334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer